John is a senior executive with over 25 years experience at transforming technology-based companies into product-based organizations. He combines a unique set of strategic, financial, talent management, and operating skills to identify unmet medical needs optimizing an organization to translate cutting–edge technology into products that address our most pressing hard to treat diseases.
Prior to co-founding and joining Cour, John was Co-Founder and CEO of Tolera Therapeutics. He led the company from initial start up through manufacturing optimization, pre-clinical, completion of a phase 2 clinical trial and filing of a Phase 3 Special Protocol Assessment (SPA) with the FDA. The company built significant barriers to entry by achieving several orphan drug designations and issuance of composition of matter patents utilizing a unique patent strategy.
Prior to Tolera, he was President and CEO of Third Wave Technologies (NASDAQ: TWTI), a biotechnology company, where he led the transformation of a non-sustainable research tools business into a robust growth driven molecular diagnostics company primarily by leading the development of hard to detect infections and cancers. Third Wave was eventually sold for $600 million. John also served as a strategic consultant to DEKALB Genetics Corporation that was ultimately sold for $2.8 billion. John was with the Spencer Stuart and Egon Zehnder life sciences practice groups where he consulted with biotech and pharmaceutical firms. Receiving his BS – Accounting from Northern Illinois University in 1983, John started his career at Arthur Andersen and also worked for Price Waterhouse. He received his MBA from the Kellogg School of Management at Northwestern University.
Dr. Daniel Getts is an energetic executive focused on translating cutting edge scientific breakthroughs into meaningful medical therapies. Placing himself at the center of the academic/industry interface Dr. Getts uniquely melds his business, pathology and immunology understanding to identify value creating strategic and product development opportunities.
Dr. Getts also holds a visiting academic position at Northwestern University and is Deputy Editor of Cellular Immunology. He has over twenty-eight patent / applications and has published his academic work in top tier scientific journals including Nature Biotechnology, the Journal of Experimental Medicine and The Proceedings of The National Academy of Science. In the last 3 years he has obtained in excess of $2 million in grant funding.
Prior to co-founding Cour, Daniel was Director Of Research & Development at Tolera Therapeutics Inc, and was pivotal in moving the lead compound from proof-of-concept into Phase 3. Daniel was a key member of the senior management team leading the company’s R&D efforts and most importantly was instrumental in developing the company’s intellectual property, while supporting the clinical, regulatory & financing programs of the company. In these roles he assisted in raising over $10 million in venture capital and $2 million in non-dilutive capital. Before his time at Tolera, Dr. Getts was Managing Director of his own Life Science Consultancy that assisted in licensing, venture capital diligence support, product & market valuations and medical writing. Dr Getts holds a Masters of Business (MBA), from Western Michigan University (2012), a Ph.D. in Medicine (2008) and a Bachelor of Medical Science (1st Class Honors, 2004) from the University of Sydney.
Jim is a financial and operations executive with over 25 years experience spanning finance, product development, manufacturing and regulatory, in both diagnostics and therapeutics. Jim co-founded Tolera Therapeutics, where he worked with CEO John Puisis to raise $20 million and bring its MAb therapy from pre-clinical to a Phase 3 Special Protocol Assessment upon. Prior to this, Jim served as CFO for Third Wave Technologies (NASDAQ: TWTI), where he oversaw long-range and annual planning, company-wide systems and infrastructure development, operational management as well as quality system oversight. Jim oversaw the company’s first FDA 510k filing for a molecular diagnostic and the launch of its multiplexing diagnostic platform. Jim is a graduate of the University of Notre Dame and the University of Chicago (MBA).